Showing results (1-10 of 522) with videos related to
Sort By:
Pageof 53
Blood|December 28, 2018
Imaging in multiple myeloma: How? When?Elena Zamagni, Paola Tacchetti, Michele CavoExpert Review of Hematology|March 28, 2018
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapyElena Zamagni, Paola Tacchetti, Lucia Pantani, et al.Expert Review of Anticancer Therapy|March 4, 2014
Maintenance therapy in newly diagnosed multiple myeloma: current recommendationsAnnamaria Brioli, Paola Tacchetti, Elena Zamagni, et al.Journal of Clinical Medicine|November 4, 2020
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma PatientsElena Zamagni, Paola Tacchetti, Simona Barbato, et al.Cancers|July 13, 2024
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple MyelomaPaola Tacchetti, Simona Barbato, Katia Mancuso, et al.Seminars in Thrombosis and Hemostasis|April 2, 2011
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosisElena Zamagni, Annamaria Brioli, Paola Tacchetti, et al.Expert Opinion on Biological Therapy|December 9, 2024
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myelomaKatia Mancuso, Simona Barbato, Marco Talarico, et al.Cancers|May 14, 2025
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANSKatia Mancuso, Marco Talarico, Enrica Manzato, et al.British Journal of Haematology|August 14, 2012
The role of imaging techniques in the management of multiple myelomaElena Zamagni, Michele CavoEuropean Journal of Haematology|July 13, 2004
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failurePatrizia Tosi, Elena Zamagni, Claudia Cellini, et al.Pageof 53